Objective:To study the effectiveness of bipolar electrocoagulation cutting technology and traditional ultrasonic scalpel cutting technology in Da Vinci robot-assisted thyroid carcinoma surgery. Methods:We retrospectively reviewed 154 patients with thyroid carcinoma who had undergone ultrasonic scalper (US, n = 81) or Maryland bipolar electrocoagulation (MB, n = 73) cutting in Da Vinci robotic surgery. The operation time, complications, efficacy and other clinical indicators were compared between the two groups. Results:The operation time of the MB group was significantly reduced (p < 0.05), and the drainage volume was significantly higher than that of the US group (p < 0.05). The postoperative PTH and serum calcium levels of total thyroidectomy in the MB group were higher than those in the US group (p < 0.05), which were (US: 2.07 ± 1.51, MB: 2.42 ± 1.46) and (US: 2.15 ± 0.14, MB: 2.20 ± 0.13). Conclusion:Bipolar coagulation cutting technology is more precise. Its application in robotic thyroid surgery can significantly shorten the operation time and protect parathyroid function, which has better clinical application prospects.

Hepatocellular carcinoma (HCC) remains a formidable challenge in oncology, characterized by high metastatic potential and recurrence rates. Traditional microwave ablation technique faces limitations due to operator dependency and potential complications. To address these challenges, we developed micron-sized polyacrylamide-iron carbonyl magnetic hyperthermia microspheres (PAM@Fe(CO)5 MSs) for non-invasive magnetic thermal ablation (MTA). These microspheres, synthesized via the SPG membrane emulsification technique, exhibit commendable biocompatibility, size stability, and robust magnetic thermal effects. When combined with PD-1 monoclonal antibody immunotherapy, PAM@Fe(CO)5 MSs demonstrated significant synergistic effects, leading to the markedly curtailed growth of metastatic tumors in mouse models. Further, in a rabbit orthotopic liver tumor model, MTA using PAM@Fe(CO)5 MSs showcased excellent safety and efficacy, with minimal impact on liver function and no observable toxicity in critical organs. This innovative approach not only enhances anti-tumor efficacy by activating the host's T-cell immune response but also overcomes the immune-suppressive tumor microenvironment. Our findings suggest that combining MTA with immunotherapy may offer a viable treatment approach for HCC and possibly other solid tumors, paving the way for safer and more effective clinical applications.

PURPOSE:This study aimed to develop and validate 2 preoperative ultrasound (US)-based risk-scoring systems to predict axillary lymph node (ALN) metastasis and the number of metastatic ALNs (≤ 2 vs. > 2) in patients with breast cancer. METHOD:A multicenter retrospective study included 1194 women with breast cancer from 3 institutions. Institutions 1 and 2 were used for training (n = 643) and testing (n = 275), while 276 patients from Institution 3 served as the validation set. Multivariate logistic regression was used to construct 2 risk-scoring systems based on US features. Predictive performance was assessed using area under the curve (AUC), calibration plots, and decision curve analysis. RESULTS:The risk-scoring system for ALN metastasis (presence vs. absence), based on the longest diameter and margin of the mass, mass pathology, long-to-short axis ratio of the ALN, cortical morphological features, and blood flow type of the ALN, achieved AUCs of 0.86, 0.81, and 0.84 in the training, testing, and validation sets, respectively. The risk-scoring system for predicting the number of metastatic ALNs (≤ 2 vs. >2), based on US (the longest diameter and the number of suspicious ALNs on US), achieved AUCs of 0.78, 0.75, and 0.78 in the training, testing, and validation sets, respectively. Calibration plots showed good model calibration, and decision curve analysis confirmed the clinical utility of both models. CONCLUSION:The 2 preoperative US-based risk-scoring systems effectively predicted ALN metastasis and the number of metastatic ALNs, aiding clinicians in assessing the risk of ALN involvement in breast cancer patients.

Intraoperative radiotherapy (IORT) has been used as a novel therapeutic alternative for breast-conserving surgery (BCS) in patients with breast cancer. However, the long-term outcomes and safety of IORT in patients with breast cancer remain incompletely understood. Therefore, the present study aimed to explore the long-term outcomes of IORT following BCS, focusing on the oncological outcomes and cosmetic consequences compared with postoperative RT (PORT) in patients with breast cancer. Patients with early-stage breast cancer who underwent BCS followed by IORT or PORT between January 2016 and October 2020 at the Research Institute of General Surgery, Jinling Hospital, Nanjing Medical University (Nanjing, China), were retrospectively reviewed. After screening, a total of 59 patients were included in the present study and divided into two groups according RT records as follows: The IORT group (n=21) and the PORT group (n=38). The clinical data of all patients, including surgical and RT complications, cosmetic grading and scoring, and other events, were collected and retrospectively analyzed. No significant difference was observed in terms of the mean follow-up time in the IORT (5.89±1.57 years) and PORT (6.09±1.60 years) groups (P>0.05). Compared with PORT, IORT showed non-inferior therapeutic efficacy, with no significant differences in postoperative complications (surgical site infection and chronic pain; P>0.05). Notably, the IORT group achieved superior cosmetic outcomes, with 95.2% (20/21) of patients achieving a rating of excellent/good vs. 44.7% (17/38 patients) in the PORT group (P<0.001), alongside higher median cosmetic scores at all postoperative intervals (P<0.01). IORT also reduced healthcare utilization, shortening hospitalization by 23.8 days (12.1±5.1 vs. 35.9±3.5 days; P<0.001) and lowering costs significantly (33,117.98±6,281.17 vs. 77,789.55±7,000.90 CNY; P<0.001). These findings suggest that IORT offers comparable safety, improved cosmesis and greater cost-effectiveness than PORT, supporting its integration into clinical practice for eligible patients.

Erectile dysfunction (ED) is a common clinical condition that mainly affects men aged over 40 years. Various causes contribute to the progression of ED, including pelvic nerve injury, diabetes, metabolic syndrome, age, Peyronie’s disease, smoking, and psychological disorders. Current treatments for ED are limited to symptom relief and do not address the root cause. Stem cells, with their powerful ability to proliferate and differentiate, are a promising approach for the treatment of male ED and are gradually gaining widespread attention. Current uses for treating ED have been studied primarily in experimental animals, with most studies observing improvements in erectile quality as well as improvements in erectile tissue. However, research on stem cell therapy for human ED is still limited. This article summarizes the recent literature on basic stem cell research on ED, including cavernous nerve injury, aging, diabetes, and sclerosing penile disease, and describes mechanisms of action and therapeutic effects of various stem cell therapies in experimental animals. Stem cells are also believed to interact with host tissue in a paracrine manner, and improved function can be supported through both implantation and paracrine factors. To date, stem cells have shown some preliminary promising results in animal and human models of ED.

Background It has been demonstrated that cryoablation (Cryo) causes specific T-cell immune responses in the body; however, it is not sufficient to prevent tumor recurrence and metastasis. In this report, we evaluated changes in the tumor immune microenvironment (TIME) in distant tumor tissues after Cryo and investigated the immunosuppressive mechanisms that limit the efficacy of Cryo. Methods Bilateral mammary tumor models were established in mice, and we first observed the dynamic changes in immune cells and cytokines at different time points after Cryo. Then, we confirmed that the upregulation of PD-1 and PD-L1 signaling in the contralateral tumor tissue was closely related to the immunosuppressive state in the TIME at the later stage after Cryo. Finally, we also evaluated the synergistic antitumor effects of Cryo combined with PD-1 monoclonal antibody (mAb) in the treatment of breast cancer (BC) mouse. Results We found that Cryo can stimulate the body's immune response, but it also induces immunosuppression. The elevated PD-1/PD-L1 expression in distant tumor tissues at the later stage after Cryo was closely related to the immunosuppressive state in the TIME but also created the conditions for Cryo combined with PD-1 mAb for BC mouse treatment. Cryo + PD-1 mAb could improve the immunosuppressive state of tumors and enhance the Cryo-induced immune response, thus exerting a synergistic antitumor effect. Conclusions The PD-1/PD-L1 axis plays an important role in suppressing Cryo-induced antitumor immune responses. This study provides a theoretical basis for Cryo combined with PD-1 mAb therapy in clinical BC patients.

Total flavones of Selaginella uncinata (Desv.) spring has inhibitory effects on cancer progression. The study aims to analyze the effects of total flavones of Selaginella uncinata on breast cancer cell tumor properties and the possible mechanism. MDA-MB-231 cells were treated with total flavones of Selaginella uncinata or transfected with anti-microRNA-negative control or anti-microRNA-1269. In addition, microRNA-negative control or microRNA-1269 mimics-transfected MDA-MB-231 cells were exposed to total flavones of Selaginella uncinata. Cell proliferation and apoptosis were investigated via cell counting kit-8, cell colony formation or flow cytometry analysis. MicroRNA-1269, cleaved caspase-3 or cleaved caspase-9 expression was determined through quantitative polymerase chain reaction or Western blotting. After total flavones of Selaginella uncinata treatment, the cell proliferation inhibition rate, cell apoptosis rate, cleaved caspase-3 and cleaved caspase-9 protein levels were increased, the number of cell colonies was decreased, and microRNA-1269 was downregulated in a dose-dependent way. Relative to MCF-10A cells, microRNA-1269 expression was upregulated in MDA-MB-231 cells. After transfection of anti-microRNA-1269, cell apoptosis rate, cleaved caspase-3 and cleaved caspase-9 protein levels and the cell proliferation inhibition rate were increased, but cell colony-forming ability was decreased. After treatment of microRNA-1269 mimics and total flavones of Selaginella uncinata, the cell proliferation inhibition rate, cell apoptosis rate, cleaved caspase-3 and cleaved caspase-9 protein levels were reduced and cell colony-forming ability was promoted. Total flavones of Selaginella uncinata can inhibit the proliferation and cell colony-forming ability and induce apoptosis of breast cancer cells via negatively modulating microRNA-1269.

To develop and validate an ultrasound (US) radiomics-based nomogram for the preoperative prediction of the lymphovascular invasion (LVI) status in patients with invasive breast cancer (IBC). In this multicentre, retrospective study, 456 consecutive women were enrolled from three institutions. Institutions 1 and 2 were used to train (n = 320) and test (n = 136), and 130 patients from institution 3 were used for external validation. Radiomics features that reflected tumour information were derived from grey-scale US images. The least absolute shrinkage and selection operator and the maximum relevance minimum redundancy (mRMR) algorithm were used for feature selection and radiomics signature (RS) building. US radiomics-based nomogram was constructed by using multivariable logistic regression analysis. Predictive performance was assessed with the receiving operating characteristic curve, discrimination, and calibration. The nomogram based on clinico-ultrasonic features (menopausal status, US-reported lymph node status, posterior echo features) and RS yielded an optimal AUC of 0.88 (95

BACKGROUND:Breast neuroendocrine carcinoma (NEC) is a rare malignancy with unclear treatment options and prognoses. This study aimed to construct a high-quality model to predict overall survival (OS) and breast cancer-specific survival (BCSS) and help clinicians choose appropriate breast NEC treatments.PATIENTS AND METHODS:A total of 378 patients with breast NEC and 349,736 patients with breast invasive ductal carcinoma (IDC) were enrolled in the Surveillance, Epidemiology, and End Results (SEER) database between 2010 and 2018. Propensity score matching (PSM) was performed to balance the clinical baseline. Prognostic factors determined by multivariate Cox analysis were included in the nomogram. C-index and calibration curves were used to verify the performance of the nomogram.RESULTS:Nomograms were constructed for the breast NEC and breast IDC groups after PSM. The C-index of the nomograms ranged from 0.834 to 0.880 in the internal validation and 0.818-0.876 in the external validation, indicating that the nomogram had good discrimination. The risk stratification system showed that patients with breast NEC had worse prognoses than those with breast IDC in the low-risk and intermediate-risk groups but had a similar prognosis that those in the high-risk group. Moreover, patients with breast NEC may have a better prognosis when undergoing surgery plus chemotherapy than when undergoing surgery alone or chemotherapy alone.CONCLUSIONS:We established nomograms with a risk stratification system to predict OS and BCSS in patients with breast NEC. This model could help clinicians evaluate prognosis and provide individualized treatment recommendations for patients with breast NEC.

Objective With the aim of standardizing and improving the use of ultrasound-guided PLA on PTMC, a panel of experts from China and Italy, jointly issued this expert consensus on the clinical use of PLA for low-risk PTMC. Methods This expert consensus was developed by Chinese and Italian experts who have specific competence and expertise in this area. An evidence-based approach combining the knowledge and practical experience of the panelists was utilized. Results Twenty-six expert consensus recommendations were developed, spanning topics including the indications and contraindications of PLA for PTMC, physician training, preoperative preparation of patients, intraoperative technical procedures, possible complications, efficacy assessment, follow-up strategy, the approach to new PTMC and metastatic lymph nodes after treatment, thyroid-stimulating hormone inhibition therapy, and quality control of the entire procedure. Conclusion We summarized practical recommendations about standardized and improved PLA treatment for PTMC.

Background: Breast cancer (BRCA) is the most common cancer worldwide and a serious threat to human health. MDN1 mutations have been observed in several cancers. However, the associations of MDN1 mutation with tumor mutation burden (TMB) and prognosis of BRCA have not been investigated. Methods: Genomic, transcriptomic, and clinical data of 973 patients with BRCA from The Cancer Genome Atlas (TCGA) database were analyzed. The clinical attributes of BRCA based on the MDN1 mutation status were assessed by comparing TMB and tumor infiltrating immune cells. Gene ontology analysis and gene set enrichment analysis (GSEA) were conducted to identify the key signaling pathways associated with MDN1 mutation. Moreover, univariate and multivariate Cox regression analyses were performed to assess the association between prognostic factors and survival outcomes. Finally, nomograms were used to determine the predictive value of MDN1 mutation on clinical outcomes in patients with BRCA. Results: MDN1 was found to have a relatively high mutation rate (2.77%). Compared to the MDN1 wild-type patients, the TMB value was significantly higher in MDN1 mutant patients (p < 0.001). Prognostic analysis revealed that MDN1 mutant patients had a worse survival probability than MDN1 wild-type patients (hazard ratio = 2.91; 95% CI:1.07-7.92; p = 0.036). GSEA revealed samples with MDN1 mutation enriched in retinol metabolism, drug metabolism cytochrome P450, glucuronidation, miscellaneous transport, and binding event pathways. Conclusion: MDN1 mutation was found to be associated with high TMB and inferior prognosis, suggesting that MDN1 mutation may play a potential role in prognosis prediction and immunotherapy guidance in BRCA.

Purpose: The aim of this study was to establish individualized nomograms to predict survival outcomes in older female patients with stage IV breast cancer who did or did not undergo local surgery, and to determine which patients could benefit from surgery. Methods: A total of 3,129 female patients with stage IV breast cancer aged ≥70 years between 2010 and 2015 were included in the Surveillance, Epidemiology, and End Results program. Multivariate Cox regression analysis was used to identify risk factors for overall survival (OS) and breast cancer-specific survival (BCSS). Survival analysis was performed using the Kaplan–Meier plot and log-rank test. Nomograms and risk stratification models were constructed. Results: Patients who underwent surgery had better OS (HR = 0.751, 95% CI [0.668–0.843], P < 0.001) and BCSS (HR = 0.713, 95% CI [0.627–0.810], P < 0.001) than patients who did not undergo surgery. Patients with human epidermal growth factor receptor 2-positive, lung or liver metastases may not benefit from surgery. In the stratification model, low-risk patients benefited from surgery (OS, HR = 0.688, 95% CI [0.568–0.833], P < 0.001; BCSS, HR = 0.632, 95% CI [0.509–0.784], P < 0.001), while patients in the high-risk group had similar outcomes (OS, HR = 0.920, 95% CI [0.709–1.193], P = 0.509; BCSS, HR = 0.953, 95% CI [0.713–1.275], P = 0.737). Conclusion: Older female patients with stage IV breast cancer who underwent surgery had better OS and BCSS than those who did not in each specific subgroup. Patients in low- or intermediate-risk group benefit from surgery while those in the high-risk group do not.

目的 探讨背阔肌肌皮瓣联合假体在乳腺癌改良根治术后即刻乳房重建中的应用效果.方法 自2016年1月至2019年12月,应用背阔肌肌皮瓣联合假体进行乳腺癌改良根治术后即刻乳房重建16例.回顾该方法一期术前准备、术中设计、手术过程、术后随访、二期乳头乳晕再造和局部修整过程,分析并发症发生原因并提出改进措施.结果 所有病例成功完成一期重建手术,2例患者完成二期乳头、乳晕再造和脂肪移植手术.手术并发症包括供瓣区血清肿、残余乳房皮瓣边缘坏死等,再造乳房外观缺陷包括上极不饱满、下皱襞不对称、瘢痕增生挛缩等.通过VAS量表评价再造乳房外观患者满意度,非常满意8例,满意5例,不满意3例.结论 背阔肌肌皮瓣联合假体一期重建乳房效果可靠,二期进行乳头、乳晕再造和脂肪移植修整后能取得良好效果.

Objective:To compare the survival and prognostic factors of intraoperative radiotherapy (IORT) and postoperative radiotherapy (PORT) in female patients, aged≥50 years, diagnosed with node-negative breast cancer (≤ 3 cm in size).Methods:Clinical data of eligible early breast cancer patients between 2010 and 2015 were obtained from the SEER database. Patients were divided into the IORT and PORT groups according to the radiotherapy record and propensity score matching (PSM) was subsequently conducted. Kaplan-Meier curve was used to evaluate the overall survival (OS) and breast cancer-specific survival (BCSS) between two groups and Cox proportional hazard regression analysis was used to explore the risk factors of clinical prognosis.Results:7 068 patients were included after PSM. The median follow-up time was 32.0 months. The 5-year OS rates in the IORT and PORT groups were 96.8% and 93.8%, respectively. Univariate Cox analysis showed that radiotherapy, age, histological grade, T stage, estrogen receptor (ER) status and progesterone receptor (PR) status were the independent risk factors for OS, and histological grade, T stage, ER status, PR status and chemotherapy were the independent risk factors for BCSS. Multivariate Cox regression analysis demonstrated that patients who received IORT had better OS than PORT counterparts ( P=0.020). Besides, patients aged≥60 years obtained worse OS than those aged<60 years ( P=0.003). Patients with T 2 stage or ER-negative tumors had worse OS than those with T 1 stage tumors ( P<0.001) or ER-positive tumors ( P=0.001). Patients with grade Ⅲ-Ⅳ tumors achieved worse BCSS ( P=0.004). Subgroup analysis showed that IORT yielded better OS for elderly patients (≥60 years), grade Ⅲ-Ⅳ tumors, infiltrating duct carcinoma, T 2 stage tumors, ER-positive tumors, PR-positive tumors and patients without chemotherapy. Conclusions:IORT may bring benefit for highly selected patients with low risk of recurrence, which is not inferior to PORT in terms of short-term survival. Prospective studies with longer follow-up time are needed to confirm the findings.

肠道菌群作为肠道微生物的一部分,在促进人体健康发育方面有着重要作用,但同时也能导致人体出现炎症、肿瘤等.甲状腺癌是人体内分泌系统和头颈部最易发的恶性肿瘤,且在全球数据统计中,其发病率逐步攀升,严重影响了人们的身心健康.甲状腺癌的发生发展与肠道菌群失调有着一定的联系,本文就肠道菌群与甲状腺癌之间的相关性进行综述,以期为甲状腺癌的防治提供新思路.

Background Neuroendocrine carcinoma (NEC) of the breast is a very rare malignant tumor whose clinic pathological features and prognosis are not well defined. The aim of this study was to compare the clinic pathological features and clinical outcome between breast neuroendocrine carcinoma and breast invasive ductal carcinoma (IDC) and to know the independent prognostic risk factors of NEC. Method Patients with breast NEC and breast IDC were identified through the Surveillance, Epidemiology, and End Results (SEER) database from 2010 to 2015. Then we compared the clinic pathological features and outcome between the two cohorts. Propensity score matching (PSM) was performed to balance the effects of baseline clinic pathological differences. Potential prognostic factors of breast NEC were identified by the univariate and multivariate Cox analysis. Results In total, we identified 208 patients with breast NEC and 275,878 cases with breast IDC.Compared with IDC, NEC was significantly correlated with higher stage, larger tumor size, more distant transfers and no population of HER2 enriched subtype. There were significant differences on the choice of treatment therapy between NEC and IDC (p=0.000). More patients chose not to undergo surgery (35.1% vs. 9.0%), and fewer patients chose breast conserving surgery than IDC patients (32.2% vs. 51.1%). Compared with IDC patients, NEC patients were more likely to choose chemotherapy (p=0.039) and more conservative in radiotherapy (p=0.000). The 66-month overall survival (OS) rate in NEC and IDC was 44.5% and 80.2% before PSM and was 49.8% and 71.4% after PSM, respectively. The 66-month breast cancer specific survival (BCSS) rate in NEC and IDC was 56.3% and 88.8% before PSM and was 54.1% and 80.5% after PSM, respectively. Finally, we identified independent prognostic factors, age, stage, pathological type, distant metastasis, chemotherapy, and molecular typing. Conclusions Breast NEC has distinct clinic pathological features and a significantly worse clinical outcome than common IDC.

颗粒脂肪移植是乳房重建术后修饰整形的重要手段,目前也已成为乳房重建的重要方法之一.本文从大体积颗粒脂肪移植、小体积颗粒脂肪移植两方面阐述颗粒脂肪在乳房重建过程中的应用,介绍纳米脂肪、脂肪来源干细胞、富血小板血浆等新技术的应用,并探讨脂肪移植对乳腺癌术后肿瘤安全性的影响.

Objective To evaluate the clinical efficacy and safety of intraoperative radiotherapy in breast conservative surgery for breast cancer patients. Methods The databases including CNKI, VIP, Wanfang, PubMed, Cochrane, Web of Science, Embase were retrieved to identify clinical trials which investigated the efficacy and safety of intraoperative radiotherapy in breast conservative surgery from the date of establishment to December 20, 2018. Two researchers independently performed literature screening, data extraction, and methodological quality evaluation according to the inclusion and exclusion criteria. An meta-analysis of the included studies was performed using RevMan 5.3 software. Results Totally 12 clinical trials (6 277 subjects) including 8 randomized controlled trials (RCT) and 4 non-RCT were enrolled. Meta-analysis showed that the local recurrence rate in patients with intraoperative radiotherapy was significantly higher than that in patients with postoperative radiotherapy (RR=2.78, 95%CI: 1.25-6.19, P=0.01), and the wound healing time was significantly longer [mean difference (MD)=5.92, 95%CI: 5.46-6.37, P<0.01]. There was no significant difference in distant metastasis rate and overall survival between intraoperative radiotherapy group and postoperative radiotherapy group (RR=0.92, 95%CI: 0.62-1.37, P=0.68; RR=1.01, 95%CI: 1.00-1.01, P=0.26). The patients undergoing intraoperative radiotherapy had significantly better cosmetic effect compared with the patients with postoperative radiotherapy (RR=1.17, 95%CI: 1.05-1.31, P<0.01). The fat liquefaction rate and exudation rate presented no significant difference between intraoperative radiotherapy group and postoperative radiotherapy group(RR=2.18, 95%CI: 0.71-6.72, P=0.18; RR=1.55, 95%CI: 0.36-6.68, P=0.56). Conclusion Intraoperative radiotherapy is not inferior to postoperative radiotherapy in distant metastasis rate, overall survival and adverse reaction, but with better cosmetic effect and a higher local recurrence rate, so the patients with low risk of recurrence are recommended. Key words: Breast neoplasms; Meta-analysis; Radiotherapy; Breast conservative surgery

Papillary thyroid cancer (PTC) accounts for 80% of all thyroid cancers and seriously impacts the quality of people's lives. Long noncoding RNAs (lncRNAs) play an important role in PTC. In previous studies, thousands of lncRNAs were screened to study their potential relationships with PTC. The aim of this study was to investigate the effect of RPL34-AS1 in PTC and to explore its potential mechanisms. Bioinformatic analyses were performed to characterize the possible function and biological features of RPL34-AS1. Apoptosis, proliferation, and invasion were detected to assess the effect of RPL34-AS1. Cell proliferation was measured using a Cell Counting Kit-8 assay. Western blot analysis was used to assess the apoptosis proteins Bax and Bcl-2. Cell invasion was measured using a Transwell assay. Quantitative real-time polymerase chain reaction (qRT-PCR) analysis was performed to examine RPL34-AS1, miR-3663-3P, and RGS4 expression. Dual-luciferase assay was performed to assess the binding of miR-3663-3P by RPL34-AS1. RIP experiment was used to verify the combination between miR-3663-3p and RGS4. We found that overexpression of RPL34-AS1 could inhibit proliferation and invasion while promoting apoptosis in PTC cell lines. Moreover, RPL34-AS1 could also competitively bind miR-3663-3p and exert its function by regulating the miR-3663-3p/RGS4 in PTC cell lines. We found a previously uncharacterized lncRNA, RPL34-AS1, and studied its function and mechanism in PTC. Our research will provide new insights into PTC and new clues for its clinical treatment.